This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spieker, L. E. Articles by Lüscher, T. F. Search for Related Content PubMed PubMed Citation Articles by Spieker, L. E. Articles by Lüscher, T. F.

REVIEW ARTICLE

Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?

^a Cardiovascular Center, Cardiology Department, University Hospital, Zürich, Switzerland

Manuscript received September 27, 2000; revised manuscript received January 4, 2001, accepted January 24, 2001.

Reprint requests and correspondence: Dr. Thomas F. Lüscher, University Hospital, Ramistrasse 100, CH - 8091 Zürich, Switzerland
cardiotfl{at}gmx.ch

Congestive heart failure (CHF) is characterized by impaired left ventricular function, increased peripheral and pulmonary vascular resistance and reduced exercise tolerance and dyspnea. Thus, mediators involved in the control of myocardial function and vascular tone may be involved in its pathophysiology. The family of endothelins (ET) consists of four closely related peptides, ET-1, ET-2, ET-3 and ET-4, which cause vasoconstriction, cell proliferation and myocardial effects through activation of ET_A receptors. In contrast, endothelial ET_B receptors mediate vasodilation via release of nitric oxide and prostacyclin. In addition, ET_B receptors in the lung are a major pathway for the clearance of ET-1 from plasma. Thus, infusion of an ET_A-receptor antagonist into the brachial artery in healthy humans leads to vasodilation, whereas infusion of an ET_B-receptor antagonist causes vasoconstriction. Endothelin-1 plasma levels are elevated in CHF and correlate both with hemodynamic severity and symptoms. Plasma levels of ET-1 and its precursor, big ET-1, are strong independent predictors of death after myocardial infarction as well as in CHF. Endothelin-1 contributes to increased systemic and pulmonary vascular resistance, vascular dysfunction, myocardial ischemia and renal impairment in CHF. Selective ET_A, as well as combined ET_A/B-receptor antagonists, have been studied in patients with CHF, and their use has shown impressive hemodynamic improvement (i.e., reduced peripheral vascular and pulmonary resistance as well as increased cardiac output). These results indicate that ET-receptor antagonists, indeed, have a potential to improve hemodynamics, symptoms and, potentially, prognosis in patients with CHF, which still carries a high mortality.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   ANP = atrial natriuretic peptide   CAD = coronary artery disease   CHF = congestive heart failure   ET = endothelin   MHC = myosin heavy chain   MI = myocardial infarction   NO = nitric oxide

This article has been cited by other articles:

				A. GLUBA, M. BANACH, D. P. MIKHAILIDIS, and J. RYSZ Genetic Determinants of Cardiovascular Disease: The Renin-Angiotensin-Aldosterone System, Paraoxonases, Endothelin-1, Nitric Oxide Synthase and Adrenergic Receptors In Vivo, September 1, 2009; 23(5): 797 - 812. [Abstract] [Full Text] [PDF]

				R. Hilal-Dandan, H. He, J. L. Martin, L. L. Brunton, and W. H. Dillmann Endothelin downregulates SERCA2 gene and protein expression in adult rat ventricular myocytes: regulation by pertussis toxin-sensitive Gi protein and cAMP Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H728 - H734. [Abstract] [Full Text] [PDF]

				S K Prasad, H J Dargie, G C Smith, M M Barlow, F Grothues, B A Groenning, J G F Cleland, and D J Pennell Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study Heart, June 1, 2006; 92(6): 798 - 803. [Abstract] [Full Text] [PDF]

				E. C. Miner and W. L. Miller A Look Between the Cardiomyocytes: The Extracellular Matrix in Heart Failure Mayo Clin. Proc., January 1, 2006; 81(1): 71 - 76. [Abstract] [Full Text] [PDF]

				M. Kubanek, I. Malek, J. Kautzner, M. Hegarova, M. Wiendl, P. Lupinek, L. Karasova, and V. Lanska The value of B-type natriuretic peptide and big endothelin-1 for detection of severe pulmonary hypertension in heart transplant candidates Eur J Heart Fail, December 1, 2005; 7(7): 1149 - 1155. [Abstract] [Full Text] [PDF]

				N. Emoto, S. B. Raharjo, D. Isaka, S. Masuda, S. Adiarto, A. Y. Jeng, and M. Yokoyama Dual ECE/NEP Inhibition on Cardiac and Neurohumoral Function During the Transition From Hypertrophy to Heart Failure in Rats Hypertension, June 1, 2005; 45(6): 1145 - 1152. [Abstract] [Full Text] [PDF]

				H. Takahashi, Y. Takeishi, T. Seidler, T. Arimoto, H. Akiyama, Y. Hozumi, Y. Koyama, T. Shishido, Y. Tsunoda, T. Niizeki, et al. Adenovirus-Mediated Overexpression of Diacylglycerol Kinase-{zeta} Inhibits Endothelin-1-Induced Cardiomyocyte Hypertrophy Circulation, March 29, 2005; 111(12): 1510 - 1516. [Abstract] [Full Text] [PDF]

				D. Merkus, B. Houweling, A. H. van den Meiracker, F. Boomsma, and D. J. Duncker Contribution of endothelin to coronary vasomotor tone is abolished after myocardial infarction Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H871 - H880. [Abstract] [Full Text] [PDF]

				A. T. Yan, R. T. Yan, and P. P. Liu Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials Ann Intern Med, January 18, 2005; 142(2): 132 - 145. [Abstract] [Full Text] [PDF]

				A. Montanari, A. Biggi, N. Carra, M. Ziliotti, E. Fasoli, L. Musiari, P. Perinotto, and A. Novarini Endothelin-A Receptors Mediate Renal Hemodynamic Effects of Exogenous Angiotensin II in Humans Hypertension, October 1, 2003; 42(4): 825 - 830. [Abstract] [Full Text] [PDF]

				D. Merkus, B. Houweling, A. Mirza, F. Boomsma, A. H van den Meiracker, and D. J Duncker Contribution of endothelin and its receptors to the regulation of vascular tone during exercise is different in the systemic, coronary and pulmonary circulation Cardiovasc Res, September 1, 2003; 59(3): 745 - 754. [Abstract] [Full Text] [PDF]

				L. E. Spieker and T. F. Luscher Endothelin receptor antagonists in heart failure--a refutation of a bold conjecture? Eur J Heart Fail, August 1, 2003; 5(4): 415 - 417. [Full Text] [PDF]

				S. S. Gottlieb The neurohormonal paradigm:have we gone too far? J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1458 - 1459. [Full Text] [PDF]

				Y. Ogata, M. Takahashi, S. Ueno, K. Takeuchi, T. Okada, H. Mano, S. Ookawara, K. Ozawa, B. C. Berk, U. Ikeda, et al. Antiapoptotic Effect of Endothelin-1 in Rat Cardiomyocytes In Vitro Hypertension, May 1, 2003; 41(5): 1156 - 1163. [Abstract] [Full Text] [PDF]

				A.-Y. Chong, A.D. Blann, and G.Y.H. Lip Assessment of endothelial damage and dysfunction: observations in relation to heart failure QJM, April 1, 2003; 96(4): 253 - 267. [Full Text] [PDF]

				R Berger and R Pacher The role of the endothelin system in myocardial infarction--new therapeutic targets? Eur. Heart J., February 2, 2003; 24(4): 294 - 296. [Full Text] [PDF]

				S.-i. Suga, N. Yasui, F. Yoshihara, T. Horio, Y. Kawano, K. Kangawa, and R. J. Johnson Endothelin A Receptor Blockade and Endothelin B Receptor Blockade Improve Hypokalemic Nephropathy by Different Mechanisms J. Am. Soc. Nephrol., February 1, 2003; 14(2): 397 - 406. [Abstract] [Full Text] [PDF]

				D. N. Muller, A. Mullally, R. Dechend, J.-K. Park, A. Fiebeler, B. Pilz, B.-M. Loffler, D. Blum-Kaelin, S. Masur, H. Dehmlow, et al. Endothelin-Converting Enzyme Inhibition Ameliorates Angiotensin II-Induced Cardiac Damage Hypertension, December 1, 2002; 40(6): 840 - 846. [Abstract] [Full Text] [PDF]

				S. Vanni, G. Polidori, I. Cecioni, S. Serni, M. Carini, and P. A. Modesti ETB Receptor in Renal Medulla Is Enhanced by Local Sodium During Low Salt Intake Hypertension, August 1, 2002; 40(2): 179 - 185. [Abstract] [Full Text] [PDF]

				R Sharma and S.D Anker From tissue wasting to cachexia: changes in peripheral blood flow and skeletal musculature Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D12 - D17. [Abstract] [PDF]

				D. Fraccarollo, J. Bauersachs, M. Kellner, P. Galuppo, and G. Ertl Cardioprotection by long-term ETA receptor blockade and ACE inhibition in rats with congestive heart failure: mono- versus combination therapy Cardiovasc Res, April 1, 2002; 54(1): 85 - 94. [Abstract] [Full Text] [PDF]

				D. Hurlimann, F. Ruschitzka, and T.F. Luscher The relationship between the endothelium and the vessel wall Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A1 - A7. [Abstract] [PDF]

				A. Montanari, N. Carra, P. Perinotto, V. Iori, E. Fasoli, A. Biggi, and A. Novarini Renal Hemodynamic Control by Endothelin and Nitric Oxide Under Angiotensin II Blockade in Man Hypertension, February 1, 2002; 39(2): 715 - 720. [Abstract] [Full Text] [PDF]

				M. G. Perry, M. M. Molero, A. D. Giulumian, P. V. G. Katakam, J. S. Pollock, D. M. Pollock, and L. C. Fuchs ETB receptor-deficient rats exhibit reduced contraction to ET-1 despite an increase in ETA receptors Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2680 - H2686. [Abstract] [Full Text] [PDF]